Vantage logo

Big-caps join the coronavirus scramble

It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.

Vantage logo

New Pfizer, same problem

Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…

Vantage logo

A new reality for Immunocore

A private raise should crystallise what was already known to have been a valuation comedown for Immunocore and its troubled investor Neil Woodford.